OPKO Health, Inc.

$1.28

+$0.01 (+0.79%)

Jan 5, 2026

Price History (1Y)

Analysis

OPKO Health, Inc. is a healthcare company specializing in diagnostics and research. It operates within the sector of Healthcare and Industry of Diagnostics & Research. With a market capitalization of $1.02B, the company has generated revenue of $642.07M (TTM), employing 2997 individuals. The company's financial health is marked by negative profitability metrics. Gross margin stands at 18.9%, while operating margin and profit margin are -35.3% and -28.1%, respectively. The return on equity is -13.3%, and the return on assets is -6.1%. OPKO Health, Inc.'s balance sheet features a debt-to-equity ratio of 30.29 and cash reserves of $411.97M, with outstanding debts totaling $395.42M. OPKO Health, Inc.'s valuation context includes a forward P/E of -4.13 and price to sales of 1.58. The revenue growth (YoY) is -12.6%, mirroring earnings growth.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About OPKO Health, Inc.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.

Visit website →

Key Statistics

Market Cap
$1.02B
P/E Ratio
N/A
52-Week High
$2.04
52-Week Low
$1.11
Avg Volume
2.80M
Beta
1.39

Company Info

Exchange
NMS
Country
United States
Employees
2,997